Clinical sequelae of complement activation in hemodialysis

Area of Science:

• Nephrology
• Immunology
• Biomaterials Science

Background:

• Clinical hemodialysis involves blood-membrane interactions activating coagulation, kallikrein, and complement pathways.
• Cuprophane membranes, widely used, cause significant blood-membrane interactions.
• Complement activation, indicated by C3a and C5a levels, is a key measure of dialysis membrane biocompatibility.

Purpose of the Study:

• To elucidate the multifaceted consequences of complement activation during hemodialysis.
• To explore the link between complement activation products and clinical manifestations in dialysis patients.

Main Methods:

• Measurement of activated complement components (C3a, C5a) during hemodialysis.
• Observation of clinical outcomes such as neutropenia, infection incidence, and organ dysfunction.

Main Results:

• Complement activation products (C3a, C5a) are elevated during hemodialysis.
• Neutropenia is an early sign of complement activation.
• Complement activation may contribute to infections, pulmonary dysfunction, and cardiac dysfunction in dialysis patients.

Conclusions:

• Complement activation during hemodialysis has widespread pathophysiological implications.
• Understanding these interactions is crucial for improving dialysis membrane biocompatibility and patient outcomes.
• Further research is needed to fully delineate the role of complement in dialysis-related complications.